{
     "PMID": "25998028",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20160118",
     "LR": "20151018",
     "IS": "1879-0631 (Electronic) 0024-3205 (Linking)",
     "VI": "140",
     "DP": "2015 Nov 1",
     "TI": "The role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin.",
     "PG": "19-28",
     "LID": "10.1016/j.lfs.2015.05.002 [doi] S0024-3205(15)00258-1 [pii]",
     "AB": "Leptin (Lep) is emerging as a pivotal molecule involved in both the early events and the terminal phases of Alzheimer's disease (AD). In the canonical pathway, Lep acts as an anorexigenic factor via its effects on hypothalamic nucleus. However, additional functions of Lep in the hippocampus and cortex have been unravelled in recent years. Early events in the sporadic form of AD likely involve cellular level alterations which can have an effect on food intake and metabolism. Thus, AD can be conceivably interpreted as a multiorgan pathology that not only results in a dramatic neuronal loss in brain areas such as the hippocampus and the cortex (ultimately leading to a significant cognitive impairment) but as a disease which also affects body-weight homeostasis. According to this view, body-weight control disruptions are to be expected in both the early- and late-stage AD, concomitant with changes in serum Lep content, alterations in Lep transport across the blood-brain barrier (BBB) and Lep receptor-related signalling abnormalities. Lep is a member of the adipokine family of molecules, while the Lep receptor belongs to the class I cytokine receptors. Since cellular response to adipokine signalling can be either potentiated or diminished as a result of specific ligand-receptor interactions, Lep interactions with other members of the adipokine family including amylin, ghrelin and hormones such as prolactin require further investigation. In this review, we provide a general perspective on the functions of Lep in the brain, with a particular focus on the sporadic AD.",
     "FAU": [
          "Folch, Jaume",
          "Patraca, Ivan",
          "Martinez, Nohora",
          "Pedros, Ignacio",
          "Petrov, Dmitry",
          "Ettcheto, Miren",
          "Abad, Sonia",
          "Marin, Miguel",
          "Beas-Zarate, Carlos",
          "Camins, Antoni"
     ],
     "AU": [
          "Folch J",
          "Patraca I",
          "Martinez N",
          "Pedros I",
          "Petrov D",
          "Ettcheto M",
          "Abad S",
          "Marin M",
          "Beas-Zarate C",
          "Camins A"
     ],
     "AD": "Unitats de Bioquimica i Farmacologia, Facultat de Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, C./ St. Llorenc 21, 43201 Reus, Tarragona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos Tercero, Madrid, Spain. Unitats de Bioquimica i Farmacologia, Facultat de Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, C./ St. Llorenc 21, 43201 Reus, Tarragona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos Tercero, Madrid, Spain. Unitats de Bioquimica i Farmacologia, Facultat de Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, C./ St. Llorenc 21, 43201 Reus, Tarragona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos Tercero, Madrid, Spain. Unitats de Bioquimica i Farmacologia, Facultat de Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, C./ St. Llorenc 21, 43201 Reus, Tarragona, Spain; Unitat de Farmacologia i Farmacognosia Facultat de Farmacia, Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain. Unitat de Farmacologia i Farmacognosia Facultat de Farmacia, Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos Tercero, Madrid, Spain. Unitat de Farmacologia i Farmacognosia Facultat de Farmacia, Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos Tercero, Madrid, Spain. Unitat de Farmacologia i Farmacognosia Facultat de Farmacia, Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos Tercero, Madrid, Spain. Centro de Biotecnologia, Universidad Nacional de Loja, Av. Pio Jaramillo Alvarado y Reinaldo Espinosa, La Argelia, Loja, Ecuador. Departamento de Biologia Celular y Molecular, C.U.C.B.A., Universidad de Guadalajara and Division de Neurociencias, Centro de Investigacion Biomedica de Occidente (CIBO), Mexico; Instituto Mexicano del Seguro Social (IMSS), Sierra Mojada 800, Col. Independencia, Guadalajara, Jalisco 44340, Mexico. Unitat de Farmacologia i Farmacognosia Facultat de Farmacia, Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos Tercero, Madrid, Spain; Centro de Biotecnologia, Universidad Nacional de Loja, Av. Pio Jaramillo Alvarado y Reinaldo Espinosa, La Argelia, Loja, Ecuador. Electronic address: camins@ub.edu.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't",
          "Review"
     ],
     "DEP": "20150519",
     "PL": "Netherlands",
     "TA": "Life Sci",
     "JT": "Life sciences",
     "JID": "0375521",
     "RN": [
          "0 (Ghrelin)",
          "0 (Islet Amyloid Polypeptide)",
          "0 (Leptin)",
          "9002-62-4 (Prolactin)"
     ],
     "SB": "IM",
     "MH": [
          "Alzheimer Disease/*physiopathology",
          "Diabetes Mellitus, Type 2/physiopathology",
          "Ghrelin/*metabolism",
          "Humans",
          "Hypothalamus/physiology",
          "Islet Amyloid Polypeptide/*metabolism",
          "Leptin/blood/metabolism/*physiology",
          "Life Style",
          "Obesity/physiopathology",
          "Prolactin/*metabolism",
          "Protein Binding"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Alzheimer's disease",
          "Amylin",
          "Ghrelin",
          "High-fat diet",
          "Hippocampus",
          "Insulin receptor",
          "Leptin",
          "Obesity",
          "PGC-1alpha",
          "Prolactin",
          "mTOR"
     ],
     "EDAT": "2015/05/23 06:00",
     "MHDA": "2016/01/19 06:00",
     "CRDT": [
          "2015/05/23 06:00"
     ],
     "PHST": [
          "2015/02/09 00:00 [received]",
          "2015/05/05 00:00 [revised]",
          "2015/05/11 00:00 [accepted]",
          "2015/05/23 06:00 [entrez]",
          "2015/05/23 06:00 [pubmed]",
          "2016/01/19 06:00 [medline]"
     ],
     "AID": [
          "S0024-3205(15)00258-1 [pii]",
          "10.1016/j.lfs.2015.05.002 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Life Sci. 2015 Nov 1;140:19-28. doi: 10.1016/j.lfs.2015.05.002. Epub 2015 May 19.",
     "term": "hippocampus"
}